Involvement of Raphe-Hippocampal Serotonergic and Septo-Hippocampal Cholinergic Mechanisms in the Penile Erection Induced by FR121196, a Putative Cognitive Enhancer

Noriaki Maeda, Nobuya Matsuoka, Mayako Yamazaki and Isamu Yamaguchi

Basic Research Group, Fujisawa Pharmaceutical Co., Ltd., 5–2–3, Tokodai, Tsukuba, Ibaraki 300–26, Japan

Received July 12, 1994 Accepted February 9, 1995

ABSTRACT—FR121196 (N-[4-acetyl-1-piperazinyl]-4-fluorobenzenesulfonamide), a putative cognitive enhancer, induced penile erection in naive rats; the dose-response curve was bell-shaped with the maximum response obtained at the dose of 3.2 mg/kg. The response to FR121196 was abolished in rats treated with intra-raphe injections of 5,7-dihydroxytryptamine or systemic injections of p-chlorophenylalanine (150 mg/kg, i.p. for three consecutive days) as well as in rats with electrolytic medial-septum lesion or surgical fimbria-fornix lesion. In addition, the penile erection induced by FR121196 (3.2 mg/kg) was dose-dependently attenuated by pindolol (0.1–3.2 mg/kg), a serotonin (5-HT) antagonist with β-antagonistic activity, but not by metoprolol, a selective β-antagonist. The inhibitory activity was shared by ICS205-930, a 5-HT₁ antagonist, but not by ketanserin, a 5-HT₂ antagonist, or sulpiride, a dopamine D₂ antagonist. Scopolamine (0.032–1 mg/kg), but not methyl-scopolamine (0.032–1 mg/kg), also attenuated the penile erection induced by FR121196. Neurochemical analysis revealed that intraperitoneal injection of FR121196 significantly elevated the levels of 5-HT and its major metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the hippocampus and that raphe-lesion significantly reduced both 5-HT and 5-HIAA levels without affecting choline-acetyltransferase activity in all cortical and subcortical regions examined. It is thus postulated that FR121196 facilitates the raphe-hippocampal serotonergic pathway resulting in an activation of the septo-hippocampal cholinergic pathway and finally induces the penile erectile response.

Keywords: FR121196, Penile erection, Septo-hippocampal pathway, Median- and dorsal-raphe nuclei

FR121196, a newly introduced putative cognitive enhancer, ameliorated memory deficit in various rat models of dementia, possibly through its action on the hippocampus (1) that plays a crucial role in memory formation (2–4). Also, the drug facilitated long term potentiation (LTP) of the mőssy fiber-CA3 system of the guinea pig hippocampal slice preparation in a manner dependent on intact cholinergic as well as somatostatinergic neuronal activities (5). Apart from the relevancy between the LTP phenomena and memory (6), which is still to be determined, FR121196 is undoubtedly a potential hippocampal activator.

FR121196 scarcely induced any behavioral changes in naive rats except for penile erection, and its effective dose as well as the dose-response curve was comparable to those for memory enhancement. Interestingly, a series of electrophysiological studies by MacLean (7) has shown that the hippocampus and its afferent are important for the expression of penile erection. The hippocampal formation is densely innervated by cholinergic nerve fibers derived from cells in the medial septum (8, 9) as well as serotonergic projections from the median and dorsal midbrain raphe nuclei (10, 11). On the other hand, cholinergic activation also induces apart from penile erections (12) yawning behavior, which is one of self grooming behaviors in rats (13, 14). Dopaminergic activation also induces yawning and penile erections (14). Activation of the serotonergic system, however, only induces penile erections (15). We thus propose that an activation of serotonergic afferents to the hippocampus may be involved in the penile erection induced by FR121196.

The present study was designed to assess the possible neuronal mechanisms underlying the penile erection induced by FR121196.
MATERIALS AND METHODS

Animals

Male Fischer 344 rats at the age of 9 weeks were purchased from Charles River Inc. (Atsugi) and housed six per cage (25.5 x 38 x 17 cm) in a temperature controlled room (22 ± 1°C) under a 12:12 light/dark cycle with lights on at 8:00. Food and water were provided ad libitum. One week later, the behavioral tests were carried out between 13:30 and 19:00 in the same room where the rats were housed. All animals were handled 3 min a day for 3 successive days before the behavioral tests. The rats were tested in groups of six, and various doses of drugs were given in semi-randomized order. Immediately after the drug injection, each rat was placed in a perspex box (17 x 27 x 13 cm) and its behavior was observed for 60 min, during which time the number of penile erections was counted. A penile erection was defined as repeated pelvic thrusts immediately followed by an upright position presenting an emerging, engorged penis which the rat proceeds to lick. Incidence of the response was counted and expressed as the number of penile erections per hour. A mirror was situated behind each box to facilitate observation of the animal.

Lesioned rats

Lesioned and sham-operated rats were assigned to receive all doses throughout a series of test sessions. Briefly, each group of six rats was administered with the vehicle or doses of a drug in the first session. In the following sessions, each of them received a dose of the drug in ascending order, and the rats that had received the largest dose were given the vehicle. In this way, the test sessions were repeated the same number of times as the total number of vehicle and drug doses. An interval of at least 3 days was provided between each session, and the series of tests was finished within 4 weeks at the longest.

Neurosurgeries

Medial-septum (MS) lesion: Handled rats were assigned to two groups: medial-septum-lesioned and sham-operated. The rats were anesthetized with pentobarbital (50 mg/kg, i.p.), placed in a stereotaxic apparatus and lesioned on the medial-septum by electrocoagulation with a radiofrequency generator (RGF-4A; Muromachi Kikai Co., Tokyo). The coordinates of the electrode placement were: 0.8 mm anterior to the bregma, on the midline, and 7.0 mm ventral from the skull surface according to the map of König and Klippel (16). A stainless-steel electrode insulated to 0.2 mm from the top was introduced, and a radiofrequency current was delivered for 60 sec with the temperature set at 60°C. The sham-operated rats were subjected to the same procedures except for electrical coagulation. The behavioral test was started 7 days after surgery.

Fimbria-fornix (FF) lesion: A micro-surgery knife (No. 715; Feather, Mino) mounted on a stereotaxic apparatus was positioned at 4.0 mm lateral to the midline, 2.0 mm posterior to the bregma and lowered 5.0 mm below the surface of the skull. The FF was transected bilaterally by driving a microknife 8.0 mm laterally and retrieving it. For the sham lesions, only the sagittal sinus was transected. The behavioral test was started 7 days after surgery.

Median- and dorsal-raphe lesion: Specific lesions of serotonergic neurons were made by stereotaxically placed local injections of 5,7-dihydroxytryptamine (5,7-DHT, in 1 μl of 0.1% ascorbic acid – 0.9% saline solution, 0.2 μl/min) through a 26-gauge cannula connected by polyethylene tubing to a gear-driven Hamilton syringe. The sham animals were injected with the vehicle. Injections into the median raphe nucleus were made at the coordinates 8.3 mm posterior to the bregma, on the midline, and 8.0 mm ventral from the skull surface; injections into the dorsal raphe nucleus were made at the coordinates 8.7 mm posterior to the bregma, on the midline, and 6.3 mm ventral from the skull surface. Both nuclei were injected with 2 μg of 5,7-DHT in a volume of 1 μl. The rats were pretreated with desipramine (25 mg/kg, i.p.) 30–45 min prior to the local injections to protect noradrenergic neurons from the lesion (17). The behavioral test was started 14 days after the lesionings.

At the end of the experiments, the placement and size of the lesions were checked by histological examination on 10-μM-thick slices subjected to Nissl staining. All animals subjected to medial-septum and FF-lesions were used for the behavioral examination; however, 3 out of 15 of the raphe-lesioned animals died within 2 weeks after surgery.

Anatomical orientation of each lesion is presented in Fig. 1.

Biochemical analysis

Brain regional monoamine contents were measured in the raphe lesioned rats by a high performance liquid chromatography (HPLC) system. Two weeks after the surgery, each rat was sacrificed by decapitation, and the whole brain was dissected out and sectioned into the following regions on ice: hippocampus; striatum; anterior part of the cortex (C1) including the prefrontal cortex; and posterior part of the cortex (C2) including the parietal, occipital and temporal cortex. The effects of FR121196 on the brain neurochemistry were also determined 30 min after i.p. injection of the drug (0.1, 1, 10, 100 mg/kg) or vehicle for its action on the brain regional contents of monoamines.

Levels of serotonin (5-HT), 5-hydroxyindoleacetic acid...
(5-HIAA), norepinephrine (NE), epinephrine (E) and dopamine (DA) were measured in stored tissues of each rat. A reverse phase HPLC method with electrochemical detection was used for quantification of monoamines. Briefly, brain tissues were extracted in 0.2 M perchloric acid (PCA) containing isoproterenol as an internal standard. The extracted solution was centrifuged at 20,000 x g for 15 min at 4°C, and the supernatant was adjusted to pH 3.0 with 1 M CH₃COONa and injected into a Eicom-pac MA50 DS liquid chromatography system equipped with an Eicom ECD100 electrochemical detector (Eicom Co., Kyoto); pump speed was 1 ml/min. The mobile phase consisted of a 0.1 M acetate-citrate buffer (pH 3.5) containing 100 μM sodium octane sulphonate as the ion pair reagent, 1 mM EDTA and 17% methylalcohol.

To characterize the changes in the integrity of brain cholinergic neurons, the choline acetyltransferase (ChAT) activity was determined in the brain of raphe-lesioned rats. The ChAT activity was measured by the method of Fonnum (18), using 14C-Acetyl Coenzyme A (New England Nuclear, MA, Boston, USA), and expressed as nmol ACh/hr/mg protein.

Proteins were measured by the method of Lowry (19).

**Fig. 1.** Schematic drawings of anatomical locations of medial-septum, fimbria-fornix and median- and dorsal-raphe lesions in a coronal section. Surgical procedures and orientations of the lesions were described in Materials and Methods. The stippled areas indicate the representative extent and placement of each lesion.

**Drugs**

FR121196 (N-[4-acetyl-1-piperazinyl]-4-fluorobenzene-sulfonamide, Fig. 2), sulpiride hydrochloride and ICS205-930 ((3-tropanyl)-1H-indole-3-carboxylic acid-ester HCl) were synthesized in our research laboratories. 5,7-Dihydroxytryptamine creatinine sulfate (5,7-DHT), (dl)-p-chlorophenylalanine methyl ester (PCPA), (+)pindolol hydrochloride and (±)metoprolol tartrate were purchased from Sigma (St. Louis, MO, USA). Ketanserin tartrate was purchased from Research Biochemicals, Inc. (Natick, MA, USA). Scopolamine hydrobromide and methyl-scopolamine hydrobromide were purchased from Nacalai Tesque (Kyoto). Pindolol and sulpiride was dissolved in 1% tartrate-saline with pH adjusted to 6.0-7.0. All other drugs were dissolved in physiological saline and given intraperitoneally in a volume of 1 ml/kg. Antagonists and FR121196 were injected 15 min and just before the start of the behavioral experiments, respectively.

**Fig. 2.** The chemical structure of FR121196.
Statistics

All data are expressed as the mean±S.E.M. In the behavioral experiments, statistical significance was estimated with the Mann-Whitney U-test. For comparison of brain neurochemistry between lesioned and sham or FR121196- and vehicle-treated rats, statistical analysis was made by Student’s t-test, with a P value of 0.05 or less indicating a significant difference.

RESULTS

Effects of FR121196 on penile erection in rats

Figure 3 shows penile erections in rats after an i.p. injection of FR121196. FR121196 (0.1–10 mg/kg) increased the number of penile erections in a bell-shaped dose-response curve with statistically significant and maximum increases above the spontaneous value at 1 and 3.2 mg/kg of the compound. No sign of other abnormal behavior was observed in rats dosed with FR121196 up to 10 mg/kg.

Effects of 5-HT depletion by systemic PCPA administration or lesioning the median- and dorsal-raphe nuclei on FR121196-induced penile erections

Figure 4 shows the effects of 5-HT depletion by systemic treatment with PCPA or median- and dorsal-raphe lesions and sham operation on the penile erection induced by FR121196. The doses of 0.32 (P<0.01), 1 (P<0.05) and 3.2 mg/kg (P<0.01) of FR121196 produced statistically significant erections in the saline-pretreated rats. On the other hand, pretreatment with 150 mg/kg of PCPA 72, 48 and 24 hr before the behavioral test markedly reduced the penile erection induced by FR121196, and the

![Fig. 3. Effects of FR121196 on penile erection in rats. The ordinate represents the mean number of penile erections in 1 hr following i.p. administration of FR121196. *P<0.05, **P<0.01: Statistically significant compared with the vehicle-treated group (by the Mann-Whitney U-test). Each column represents the mean±S.E.M. The number of rats tested is given in parentheses.](image)

![Fig. 4. Effects of PCPA pretreatment (a) and median- and dorsal-raphe lesion (b) on the penile erection induced by FR121196. PCPA (150 mg/kg) was administered 72, 48 and 24 hr before the behavioral test. Medial- and dorsal-raphe lesion by 5,7-DHT was performed as described in Materials and Methods. Two weeks after surgery, the behavioral tests were started and repeated as in the other lesion studies. The ordinate represents the mean number of penile erections in 1 hr following i.p. administration of FR121196. *P<0.05, **P<0.01: Statistically significant compared with the vehicle control in sham animals. #P<0.05, ##P<0.01: Statistically significant compared with the same dosed group of sham animals (by the Mann-Whitney U-test). Each column represents the mean±S.E.M. The number of rats tested is given in parentheses. a: □ Saline, □ PCPA. b: □ Sham, □ Raphe lesion.](image)
changes were statistically significant ($P < 0.05$) at 0.32 and 1 mg/kg of FR121196 compared to those in the saline-pretreated controls (Fig. 4a).

In the raphe-lesioned rats, the compound failed to induce penile erection above the spontaneous level, whereas in the sham-operated rats, a statistically significant response occurred at the doses of 1 and 3.2 mg/kg (Fig. 4b).

### Effects of septo-hippocampal cholinergic denervation on the penile erection

The effects of MS lesion and sham operation on penile erection induced by FR121196 are shown in Fig. 5a. In

![Graph](image)

**Fig. 5.** Effects of medial-septum (a) and fimbria-fornix (b) lesions on the penile erection induced by FR121196. Electrical coagulation of the medial septum and sham operation and knife cut of the fimbria-fornix and sham operation were performed as described in Materials and Methods. Seven days after surgery, the behavioral tests were started and repeated as each rat experienced all dosages of the drug with at least 3-day intervals. Ordinate represents the mean number of penile erections that were observed in 1 hr following i.p. administration of FR121196. $*P<0.05$, $**P<0.01$: Statistically significant compared with the vehicle control group in sham animals. $#P<0.05$: Statistically significant compared with the same dosed group of sham animals (by the Mann-Whitney U-test). Each column represents the mean±S.E.M. The number of rats tested is given in parentheses. a: 肌 sham, 脳 Medial-septum lesion. b: 肌 sham, 脳 Fimbria-fornix lesion.

![Graph](image)

**Fig. 6.** Effects of pindolol (a), ketanserin (b) and ICS205-930 (c) on the penile erection induced by FR121196. Each antagonist was administered 15 min before FR121196 treatment. The ordinate represents the mean number of penile erections that were observed in 1 hr following i.p. administration of FR121196. $*P<0.05$, $**P<0.01$, $***P<0.001$: Statistically significant compared with the vehicle control group in the FR121196-treated animals (by the Mann-Whitney U-test). Each column represents the mean±S.E.M. The number of rats tested is given in parentheses.
the MS lesioned rats, all doses of FR121196 failed to induce penile erection above the spontaneous level. In the sham-operated rats, however, statistically significant responses occurred at several doses with the maximum number of erections observed at 1 mg/kg.

Similar results were obtained in the FF-lesioned rats: FR121196 failed to induce penile erections above the spontaneous level (Fig. 5b).

Effects of serotonergic receptor antagonists on FR121196-induced penile erections

The effects of serotonergic receptor antagonists on the penile erection induced by FR121196 were investigated (Fig. 6 and Table 1). Doses of pindolol (0.1–3.2 mg/kg), a 5-HT1 and β-adrenoceptor antagonist (20), dose-dependently and significantly abolished the penile erection induced by 3.2 mg/kg of FR121196 (Fig. 6a), whereas metoprolol (0.32–10 mg/kg), a β-adrenoceptor-selective antagonist without 5-HT1-receptor-blocking activity, failed to affect the response (Table 1). Ketanserin (0.1–3.2 mg/kg), a 5-HT2 antagonist had little effect on the response (Fig. 6b). On the contrary, ICS205-930 (0.01–10 mg/kg), a specific 5-HT3 antagonist (21), significantly attenuated the response induced by FR121196 (Fig. 6c).

Effects of cholinergic and dopaminergic antagonists on the penile erection induced by FR121196

Table 1 summarizes the effects of scopolamine, methyl-scopolamine and sulpiride on the penile erections induced by FR121196. Scopolamine (0.032–1 mg/kg) dose-dependently reduced the number of penile erections induced by FR121196 (Table 1). The mean number of penile erections of the vehicle-vehicle administered control rats was 0.3–0.5/hr, and this value was significantly lower than that of the vehicle-FR121196 administered groups. *P<0.05, **P<0.01, ***P<0.001: Statistically significant compared with the vehicle-treated group (by the Mann-Whitney U-test).

Table 2. Changes in monoamines and ChAT activities in the brain areas of raphe-lesioned rats

Each value represents the mean ± S.E.M. Six animals were used in each group. Brain monoamines and ChAT activities were determined 2 weeks following the raphe lesion. *P<0.05, **P<0.01, ***P<0.001: Statistically significant compared to the corresponding region in the sham animals by Student’s t-test.
Fig. 7. Effects of FR121196 on brain regional monoamine contents. Doses of FR121196 (0.1, 1, 10, 100 mg/kg) or vehicle were administered i.p. 30 min before sacrifice of the animals. Brain regional monoamines were determined by HPLC as described in Materials and Methods. *P<0.05, **P<0.01: Statistically significant compared to the corresponding region of the vehicle-administered animals by Student's t-test. □ 0 mg/kg, □ 0.1 mg/kg, □ 1 mg/kg, □ 10 mg/kg, □ 100 mg/kg.
by FR121196 (3.2 mg/kg). In contrast, neither a peripheral acting muscarinic antagonist, methyl-scopolamine (0.032–1 mg/kg), nor sulpiride (1–32 mg/kg), a dopamine D₃ blocker, affected the responses induced by FR121196.

**Brain neurochemistry**

**Effects of median- and dorsal-raphe lesion by 5,7-DHT on brain regional monoamines and ChAT activities:** The levels of brain regional monoamines after median- and dorsal-raphe lesion are presented in Table 2. The treatment significantly reduced 5-HT and 5-HIAA levels in almost all the cortical and subcortical brain areas. The most striking effect was observed in the hippocampus where 5-HT and 5-HIAA were decreased by 73 and 68% of the values in sham rats, respectively. NE, DA and their metabolites in the brain areas were hardly changed in the lesioned rats compared with the sham control. On the other hand, the lesion hardly affected ChAT activities in all brain regions examined.

**Effects of intraperitoneal administration of FR121196 on brain regional monoamines:** Figure 7 illustrates the effect of systemic administration of FR121196 on the brain regional monoamine levels. Intraperitoneal injection of FR121196 significantly elevated 5-HT and 5-HIAA levels in the hippocampus in a bell-shaped dose-response manner, and the maximum increase was obtained at doses of 1 and 10 mg/kg by 125 and 121% of the respective values in vehicle-treated rats (Fig. 7a and b). A statistically significant increase in the 5-HIAA level was also observed in the posterior cortex (Fig. 7b). The drug hardly affected NE and DA levels in any other brain regions examined except for the hippocampus where the NE level was slightly but significantly increased (Fig. 7c and d).

**DISCUSSION**

MacLean (7), after a series of electrophysiological studies, concluded that the hippocampus and its afferents are important for the expression of penile erection. There are two major afferent inputs to the hippocampus: the cholinergic nerves derived from MS (8, 9) and the serotoninergic nerves from the raphe nuclei (10, 11). It is also known that the septo-hippocampal cholinergic nerve activity is controlled by dopaminergic nerves derived from the ventral tegmental area (A10) (22, 23). These histochemical mappings of the hippocampal afferents coincide with the pharmacological evidence that dopaminergic (14, 24, 25), serotoninergic (15, 26, 27) and cholinergic (12) stimulants induce penile erection.

The present study clearly demonstrated that FR121196 induced penile erection in naive rats that had been completely abolished by PCPA pretreatment or neurotoxic lesioning of the median- and dorsal-raphe using 5,7-DHT. The dose regime of PCPA-pretreatment reportedly depletes brain 5-HT levels by more than 90% (28), whereas the present neurochemical analysis showed that the raphe lesion specifically depleted 5-HT and its major metabolite 5-HIAA in the whole limbic area including the hippocampus (Table 2). The latter observation coincides with the previous findings that serotoninergic nerve terminals derived from the median- and dorsal-raphe nuclei are widely distributed in brain areas such as the cerebral cortex, septum and hippocampus (10, 11). We thus theorize that the response induced by FR121196 is mediated by an activation of serotoninergic neurons that originated in the raphe nucleus and reached the hippocampus, and this would be supported by the present finding that FR121196 increased hippocampal 5-HT and 5-HIAA. Because the ratio of 5-HT to 5-HIAA hardly changed following FR121196 treatment, both the synthesis and release of serotonin might be enhanced by the drug. In this regard, it is interesting to note that the penile erection induced by fenfluramine, a serotonin reuptake inhibitor and releaser, was also cancelled by lesioning of the median and dorsal raphe nuclei as well as by the septo-hippocampal deafferentations (29).

The present study further demonstrated that pindolol, a β-adrenoceptor antagonist with 5-HT₁-blocking activity (20), but not metoprolol, a β-adrenoceptor antagonist without 5-HT₁-blocking activity (30), dose-dependently attenuated the penile erection induced by FR121196. The finding is in line with the hypothesis that central 5-HT₁β- and/or 5-HT₁c-receptor activities play a crucial role in sexual behavior (15, 27). In addition, ICS205-930, a 5-HT₃ antagonist (21), but not ketanserin, a 5-HT₂ antagonist (31), attenuated the penile erection. These results in view of the above discussions suggest that a stimulation of 5-HT₁ and 5-HT₃ receptors through an activation of the raphe-hippocampal pathway is responsible for the penile erection induced by FR121196. In support of the assumption, a growing body of evidence indicates that not only 5-HT₁, but also 5-HT₃ receptors are densely distributed within the limbic areas including the hippocampus (32, 33). On the other hand, it has been shown that the serotoninergic raphe-hippocampal pathway exerts a powerful influence on the electrical activity of the hippocampus (34–36) whereas a direct application of 5-HT into the hippocampus or a systemic administration of 5-HT releaser increased hippocampal acetylcholine release (37, 38). Furthermore, it is interesting to note that stimulation of the 5-HT₁ receptors enhances ACh release in the hippocampus (38). An activation of the intra-hippocampal 5-HT₃ receptors is also postulated to enhance ACh release via the enhancement of 5-HT transmission (39). It is thus
tempting to speculate that FR121196 stimulates 5-HT₁ and 5-HT₃ receptors through raphe-hippocampal serotonergic activation that in turn causes hippocampal ACh release and finally leads to penile erection.

The above-mentioned speculation is substantiated by the present finding that scopolamine but not methylscopolamine attenuated the penile erection induced by FR121196. In addition, the erectile effects of FR121196 were completely abolished by MS- or FF-lesion, which has been shown to significantly reduce hippocampal ChAT activities (1). Although we have previously reported that dopaminergic stimulants, apomorphine and amantadine, induced penile erection in a manner antagonizable by scopolamine, MS- or FF-lesion (12, 40), the present data on sulpiride exclude the possible involvement of a dopaminergic mechanism in the action of FR121196. FR121196 appears to indirectly activate the septo-hippocampal cholinergic pathway through a mechanism independent from dopaminergic nerve activity to induce penile erection. In fact, FR121196 revealed little affinity for the receptors to the known mediators including acetylcholine, dopamine and serotonin (unpublished observation of N. Maeda et al.).

In conclusion, the present study strongly suggest that an indirect activation of the septo-hippocampal cholinergic pathway through effects on the raphe-hippocampal serotonergic neurons is involved in the penile erection induced by FR121196. It is noteworthy that the memory enhancing effect of the compound is cancelled not only by septo-hippocampal cholinergic (1) but also raphe-serotonergic denervation (41). A common mechanism might be involved, at least in part, in the erection stimulating and memory enhancing activities of FR121196.

REFERENCES

1 Matsuoka N, Maeda N, Yamazaki M, Ohkubo Y and Yamaguchi I: Effect of FR121196, a novel cognitive enhancer, on memory impairment of rats in passive avoidance and radial maze tasks. J Pharmacol Exp Ther 263, 436 – 444 (1992)

2 Miyamoto M, Kato J, Narumi S and Nagaoka A: Characteristics of memory impairment following lesioning of the forebrain and medial septal nucleus in rats. Brain Res 419, 19 – 31 (1987)

3 Hagan JJ, Salamone JD, Simpson J, Iversen SD and Morris RGM: Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis. Behav Brain Res 27, 9 – 20 (1988)

4 Matsuoka N, Maeda N, Ohkubo Y and Yamaguchi I: Differential effects of physostigmine and pilocarpine on the spatial memory deficits produced by two septo-hippocampal deafferentations in rats. Brain Res 559, 233 – 240 (1991)

5 Matsuoka N, Yamaguchi I and Satoh M: Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol 241, 27 – 35 (1993)

6 Teyler TJ and Discenna P: Long-term potentiation as a candidate mnemonic device. Brain Res Rev 7, 15 – 28 (1984)

7 MacLean PD: Brain mechanisms of primordial sexual functions and related behavior. In Sexual Behavior: Pharmacology and Biochemistry, Edited by Sandler M and Gessa GL, pp 1 – 11, Raven Press, New York (1975)

8 Wenk H, Bigi V and Meyer U: Cholinergic projections from magnocellular nuclei of the basal forebrain to cortical areas in rats. Brain Res Rev 2, 295 – 316 (1980)

9 Mesulam MM, Mufson EJ, Wainer BH and Levey AI: Central cholinergic pathways in the rat; an overview based on an alternative nomenclature (Ch1 – Ch6). Neuroscience 10, 1185 – 1201 (1983)

10 Amzitai C and Segal M: An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 179, 641 – 668 (1978)

11 Köhler C and Steinbusch H: Identification of serotonin and non-serotonin-containing neurons of the mid-brain raphe projecting to the entorhinal area and the hippocampal formation. A combined immunohistochemical and fluorescent retrograde tracing study in the rat brain. Neuroscience 7, 951 – 976 (1982)

12 Maeda N, Matsuoka N and Yamaguchi I: Septohippocampal cholinergic pathway and penile erection induced by dopaminergic and cholinergic stimulants. Brain Res 537, 163 – 168 (1990)

13 Ueba-Holmuen R, Gonzales RM and Holmgren B: Is yawning a cholinergic response? Nature 267, 261 – 263 (1977)

14 Gower AJ, Berendsen HHG, Proncen MM and Broekkamp CLE: The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity. Eur J Pharmacol 103, 81 – 89 (1984)

15 Berendsen HHG and Broekkamp CLE: Drug-induced penile erections in rats; indications of serotonin₁B receptor mediation. Eur J Pharmacol 135, 279 – 287 (1987)

16 König JFR and Klippel RA: The Rat Brain; A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem. Williams and Wilkins, Baltimore (1963)

17 Björklund A, Baumgarten HG and Rensch A: 5,7-Dihydroxytryptamine; Improvement of its selectivity for serotonin neurons in the CNS by pretreatment with desipramine. J Neurochem 24, 813 – 835 (1975)

18 Fonnem F: A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 24, 407 – 409 (1975)

19 Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with Folin phenol reagent. J Biol Chem 193, 265 – 275 (1951)

20 Nahorski SR and Willcoks AR: Interaction of β-adrenoceptor antagonists with 5-hydroxytryptamine receptor binding in rat cerebral cortex. Br J Pharmacol 78, 107 – 111 (1983)

21 Richardson BP, Engel G, Donatsch P and Stadler PA: Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316, 126 – 131 (1985)

22 Assaf SY and Miller JJ: excitatory action of the mesolimbic dopamine system on septal neurons. Brain Res 129, 353 – 360 (1977)

23 Di Chiara G, Porceddu ML, Vargiu L, Argiolas A and Gessa GL: Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264, 564 – 567 (1976)

24 Baraldi M and Bertolini A: Penile erections induced by amantad-
dine in male rats. Life Sci 14, 1231–1235 (1974)

25 Benassi-Benelli A, Ferrari F and Pelegrini-Quarantotti B: Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats. Arch Int Pharmacodyn Ther 241, 128–134 (1979)

26 Baraldi M, Benassi-Benelli A and Lolli M: Penile erections in rats after fenfluramine administration. Riv Farmacol Ther 8, 375–379 (1977)

27 Berendsen HHG, Jenck F and Broekkamp CLE: Involvement of 5-HT₁c-receptors in drug-induced penile erections in rat. Psychopharmacology (Berlin) 101, 57–61 (1990)

28 Stoessl AJ, Dourish CT and Iversen SD: Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents; evidence for mediation by endogenous 5-HT. Brain Res 517, 111–116 (1990)

29 Maeda N, Matsuoka N and Yamaguchi I: Possible involvement of the septo-hippocampal cholinergic and raphe-serotonergic activations in the penile erection induced by fenfluramine in rats. Brain Res 652, 181–189 (1994)

30 Hjorth S and Carlsson A: (−)-Pindolol stereospecifically inhibits rat brain serotonin (5-HT) synthesis. Neuropharmacology 24, 1143–1146 (1985)

31 Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J and Janssen PAJ: Receptor binding profile of R41 468, a novel antagonist at 5-HT₂ receptors. Life Sci 28, 1015–1022 (1981)

32 Kilpatrick GJ, Jones BJ and Tyers MB: Identification and distribution of 5-HT₃ receptors in rat brain using radioligand binding. Nature 330, 746–748 (1987)

33 Mitchell EA and Pratt JA: Neurochemical structures involved in the action of the 5-HT₁ antagonist ondansetron; a 2-deoxyglucose autoradiographic study in the rat. Brain Res 538, 289–294 (1991)

34 Assaf SY and Miller JJ: The role of raphe serotonin system in the control for septal unit activity and hippocampal desynchronization. Neuroscience 3, 539–550 (1978)

35 Richter-Levin G and Segal M: Effects of serotonin releasers on dentate granule cell excitability in the rat. Exp Brain Res 82, 199–207 (1990)

36 Vanderwolf CH: Cerebral activity and behavior. Int Rev Neurobiol 30, 225–240 (1988)

37 Ohue T, Koshimura K, Akiyama Y, Ito A, Kido T, Takagi Y and Miwa S: Regulation of acetylcholine release in vivo from rat hippocampus by monoamines as revealed by novel column-switching HPLC with electrochemical detection. Brain Res 572, 340–344 (1992)

38 Nilsson OG, Leanza G and Björklund A: Acetylcholine release in the hippocampus; regulation by monoaminergic afferents as assessed by in vivo microdialysis. Brain Res 584, 132–140 (1992)

39 Martin KF, Hannon S, Phillips I and Heal DJ: Opposing roles for 5-HT₁a and 5-HT₃ receptors in the control of 5-HT release in rat hippocampus in vivo. Br J Pharmacol 106, 139–142 (1992)

40 Maeda N, Matsuoka N and Yamaguchi I: Role of dopamine, serotoninergic and cholinergic link in the expression of penile erection in rats. Jpn J Pharmacol 66, 59–66 (1994)

41 Maeda N, Matsuoka N, Yamazaki M, Arakawa H, Ohkubo Y and Yamaguchi I: A screening concept based on a hypothesis lead to a development of a putative cognitive enhancer that stimulates penile erection. Jpn J Pharmacol 64, 147–153 (1994)